Immunoexpression of HSPA9 and CUL2 in prostatic tissue and adenocarcinoma

Hirth, Carlos Gustavo; Vasconcelos, Gislane Rocha; Cunha, Maria do Perpétuo Socorro Saldanha da; Leite, Carlos Heli Bezerra; Dornelas, Conceição Aparecida

doi:10.1016/j.anndiagpath.2021.151843

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HSPA9 is upregulated in many tumors compared to healthy tissue and is an inhibitor of complement-dependent cytotoxicity, protecting cells from antibody-based immune therapy. In a recent retrospective study of 636 RP patients, HSPA9 expression was associated with an increased risk of high-grade adenocarcinoma and biochemical failure after salvage therapy, as detected by microarrays [ 65 ]. HSPA9 is also part of a 12-biomarker panel that predicted PCa aggressiveness (surgical Gleason and TNM stage) and lethal outcome robustly in both high- and low-Gleason areas, despite biopsy-sampling error [ 66 ].…”

Section: Discussionmentioning

confidence: 99%

Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness

Lygirou

Fasoulakis

Stroggilos

et al. 2022

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most common cancer in men. Diagnosis and risk assessment are widely based on serum Prostate Specific Antigen (PSA) and biopsy, which might not represent the exact degree of PCa risk. Towards the discovery of biomarkers for better patient stratification, we performed proteomic analysis of Formalin Fixed Paraffin Embedded (FFPE) prostate tissue specimens using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Comparative analysis of 86 PCa samples among grade groups 1–5 identified 301 significantly altered proteins. Additional analysis based on biochemical recurrence (BCR; BCR+ n = 14, BCR- n = 51) revealed 197 significantly altered proteins that indicate disease persistence. Filtering the overlapping proteins of these analyses, seven proteins (NPM1, UQCRH, HSPA9, MRPL3, VCAN, SERBP1, HSPE1) had increased expression in advanced grades and in BCR+/BCR- and may play a critical role in PCa aggressiveness. Notably, all seven proteins were significantly associated with progression in Prostate Cancer Transcriptome Atles (PCTA) and NPM1NPM1, UQCRH, and VCAN were further validated in The Cancer Genome Atlas (TCGA), where they were upregulated in BCR+/BCR-. UQCRH levels were also associated with poorer 5-year survival. Our study provides valuable insights into the key regulators of PCa progression and aggressiveness. The seven selected proteins could be used for the development of risk assessment tools.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness

Lygirou

Fasoulakis

Stroggilos

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition, castration resistant prostate cancer (CRPC) is associated with increased reliance on HSP70s [ 35 ], and GRP78 expression is significantly elevated in metastatic CRPC compared with localized prostate cancer [ 36 ]. Moreover, GRP75 expression correlates with increased risk of high-grade prostate adenocarcinoma [ 37 ]. However, a report published in 2000 indicated that the expression of HSP70 molecules was unaltered in early prostate cancers but was reduced in morphologically advanced cancers compared with non-neoplastic prostate epithelium [ 38 ].…”

Section: Hsp Familymentioning

confidence: 99%

Heat Shock Protein 70 and 90 Family in Prostate Cancer

Liu

Yan

et al. 2022

Life

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most frequent cancer that affects aging men worldwide. However, its exact pathogenesis has not been fully elucidated. The heat shock protein (HSP) family has cell-protective properties that may promote tumor growth and protect cancer cells from death. On a cellular level, HSP molecules have a strong relationship with multiple important biological processes, such as cell differentiation, epithelial–mesenchymal transition (EMT), and fibrosis. Because of the facilitation of HSP family molecules on tumorigenesis, a number of agents and inhibitors are being developed with potent antitumor effects whose target site is the critical structure of HSP molecules. Among all target molecules, HSP70 family and HSP90 are two groups that have been well studied, and therefore, the development of their inhibitors makes great progress. Only a small number of agents, however, have been clinically tested in recruited patients. As a result, more clinical studies are warranted for the establishment of the relationship between the HSP70 family, alongside the HSP90 molecule, and prostate cancer treatment.

show abstract